How much funding has DELFI Diagnostics raised?

DELFI Diagnostics has raised $364.8M in total funding, most recently a Venture Round.

Who are DELFI Diagnostics's investors?

DELFI Diagnostics's investors include Menlo Ventures, OrbiMed, Samsara BioCapital, Illumina Ventures, Cowen Healthcare Investments, Foresite Capital.

When was DELFI Diagnostics founded?

DELFI Diagnostics was founded in 2019.

Where is DELFI Diagnostics headquartered?

DELFI Diagnostics is headquartered in Baltimore, Maryland, United States.

What industry is DELFI Diagnostics in?

DELFI Diagnostics operates in Artificial Intelligence, Biotech, Diagnostics.

How many employees does DELFI Diagnostics have?

DELFI Diagnostics has 51-200 employees.

DELFI Diagnostics

Saving Lives Through Early Cancer Detection

Baltimore, United States · Founded 2019 · $364.8M raised

Artificial Intelligence

Biotech

Diagnostics

Headquarters: Baltimore, Maryland
Employees: 51–200
Founded: 2019
Business Model: B2B

Website: delfiagnostics.com
Total Funding: $364.8M
Last Round: $34.3M Venture RoundDec 2025
Rounds: 4

About

DELFI Diagnostics pioneers fragmentomics technology, analyzing cell-free DNA fragments from blood samples using advanced machine learning and next-generation sequencing for early cancer detection and monitoring. Their DELFI platform scans millions of data points to identify cancer signals with high sensitivity, supporting providers and pharma in treatment decisions. Developed by experts in genomics, AI, and cancer biology.

Summary

DELFI Diagnostics is an Artificial Intelligence company based in Baltimore, United States, founded in 2019. It has raised $364.8M in total across 4 rounds, most recently a $34.3M Venture Round round in Dec 2025. Investors include Menlo Ventures, OrbiMed and Samsara BioCapital.

LinkedIn X (Twitter)